Disease relevance of roscovitine

• We reported recently that roscovitine (ROSC), a selective cyclin-dependent kinase (CDK) inhibitor, arrested human MCF-7 breast cancer cells in G2 phase of the cell cycle and concomitantly induced apoptosis [1].

High impact information on roscovitine

• Moreover, the kinetics of ROSC-induced apoptosis was delayed in the presence of phenol red [1].
• On the other hand, ROSC-induced G1 arrest observed by another group has not been accompanied by apoptosis [1].
• This complex regulation may explain the partial meiotic arrest of ROS-treated oocytes and the accelerated maturation observed after such treatment [2].
• However, in cattle maturing oocytes several cellular events such as protein synthesis and phosphorylation, chromatin condensation and nuclear envelope folding escape ROS inhibition suggesting the alternative pathways in oocyte maturation [2].
• We compared the level of synthesis and phosphorylation of several protein kinases during bovine cumulus oocyte complex (COC) maturation in vitro in the presence or not of epidermal growth factor (EGF) and ROS [2].

Biological context of roscovitine

• However, the phosphorylation of Akt but not JNKs was diminished in ROS-treated oocytes [2].
• Roscovitine (ROS), an inhibitor of M-phase promoting factor (MPF) kinase activity reversibly blocks the meiotic resumption in vitro [2].

Associations of roscovitine with other chemical compounds

• We showed that during the EGF-stimulated maturation, ROS neither affected the decrease of EGF receptor (EGFR) nor did inhibit totally its phosphorylation in cumulus cells and also did not totally eliminate tyrosine phosphorylation in oocytes [2].

Gene context of roscovitine

• However, ROS did inhibit the Phosphoinositide 3-kinase (PI3) activity when oocytes mature without EGF [2].
• Accumulation of Akt/PKB (protein kinase B), JNK1/2 (jun N-terminal kinases) and Aurora-A in oocytes during maturation was not affected by ROS [2].

References